Feds are fighting kickbacks suit out of 'animus,' judge says by Eric Sagonowsky Wednesday, April 17, 2019 A judge questioned the Justice Department's motives for dismissing whistleblower allegations that UCB paid kickbacks to boost Cimzia scripts.
Pharma's ad spending ticks upward again to $6.5B in 2018 by Beth Snyder Bulik Tuesday, April 16, 2019 Pharmaceutical ad spending continued its upward climb last year, with spending topping $6.46 billion, according to Kantar Media.
Lawmakers say enough is enough at insulin pricing hearing by Eric Sagonowsky Wednesday, April 10, 2019 After listening to some familiar back-and-forth between pharma and PBM executives, lawmakers issued one decree: Something's got to give.
NICE rejects Novartis' struggling breast cancer drug Kisqali by Kyle Blankenship Wednesday, April 10, 2019 Novartis saw an opening in the U.K. market to gain ground on competitors to its breast cancer drug Kisqali. Now that door has swung shut.
Amgen bone drug Evenity wins FDA nod, but with strings attached by Angus Liu Wednesday, April 10, 2019 On its second try, Evenity won approval only in postmenopausal women at high risk of bone fracture—and with a boxed warning.
Amgen, Novartis file dueling lawsuits over Aimovig collaboration by Eric Sagonowsky Thursday, April 4, 2019 Amgen wants to exit its collaboration with Novartis on migraine prevention drug Aimovig.
Sanofi plans sales layoffs—again—in primary care, diabetes by Eric Sagonowsky Thursday, April 4, 2019 Sanofi, hit hard by pricing pressure, is once again bringing out the job-chopping ax.
J&J launches industry-first TV ad with drug list price by Beth Snyder Bulik Friday, March 29, 2019 Johnson & Johnson’s anticoagulant Xarelto has picked up an industry first.
AZ's Farxiga won its EU nod in Type 1. How will it fare at FDA? by Angus Liu Tuesday, March 26, 2019 Increased incidence of diabetic ketoacidosis in Type 1 patients, an issue raised at Zynquista's AdCom meeting, has shown up in other SGLT trials.
As it hiked insulin prices 52%, Lilly says net prices fell 8% by Eric Sagonowsky Monday, March 25, 2019 Eli Lilly reports that Humalog's net prices have slipped by 8% in recent years even as the company raised list prices 52%.
